04-07-2020, 05:32 PM
Did I already post this? Since I'm not sure, this retrospective, single-hospital study finds benefit for ACE Inhibitors & ARB. The report/study has not yet been peer reviewed.
Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors Usage is Associated with Improved Inflammatory Status and Clinical Outcomes in COVID-19 Patients With Hypertension
The percentage of hypertension patients using ARB/ACEI was essentially the same among those infected with COVID-19 as those seen in a period before COVID-19 (34.1% vs 35.4%).
They see evidence that suggests inflammation response is involved, and suggest some specific studies be made.
Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors Usage is Associated with Improved Inflammatory Status and Clinical Outcomes in COVID-19 Patients With Hypertension
Quote:126 COVID-19 patients with preexisting hypertension at Hubei Provincial Hospital of Traditional Chinese Medicine (HPHTCM) in Wuhan from January 5 to February 22, 2020 were retrospectively allocated to ARBs/ACEIs group (n=43) and non-ARBs/ACEIs group (n=83) according to their antihypertensive medication. 125 age- and sex-matched COVID-19 patients without hypertension were randomly selected as non-hypertension controls.
Quote:Furthermore, much lower proportion of critical patients (9.3% vs 22.9%; p=0.061), and a lower death rate (4.7% vs 13.3%; p=0.216) were observed in ARBs/ACEIs group than non-ARBs/ACEIs group, although these differences failed to reach statistical significance.
The percentage of hypertension patients using ARB/ACEI was essentially the same among those infected with COVID-19 as those seen in a period before COVID-19 (34.1% vs 35.4%).
They see evidence that suggests inflammation response is involved, and suggest some specific studies be made.